Spots Global Cancer Trial Database for romiplostim
Every month we try and update this database with for romiplostim cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Safety of Romiplostim (Nplate®) Following UCBT | NCT02046291 | Hematologic Mal... | Romiplostim | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Secondary Prophylaxis in Non-Hodgkin Lymphoma (NHL) and Chemotherapy-induced Thrombocytopenia | NCT01516619 | Non-Hodgkin Lym... | Romiplostim | 18 Years - | IRCCS San Raffaele | |
| Patients With Relapsed Ovarian Cancer (2nd and 3rd Line) Treated With Chemotherapy According to AGO Guidelines | NCT03622931 | Ovarian Cancer | Standard chemot... Romiplostim Placebos | 18 Years - | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH | |
| AMG 531 in Patients With Advanced Malignancy Receiving Treatment With Carboplatin | NCT00147225 | Solid Tumors Advanced Cancer | AMG 531 Carboplatin Adriamycin Ifosfamide | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer | NCT03937154 | Chemotherapy-in... | Romiplostim Placebo | 18 Years - 100 Years | Amgen | |
| AMG 531 in Patients With Advanced Malignancy Receiving Treatment With Carboplatin | NCT00147225 | Solid Tumors Advanced Cancer | AMG 531 Carboplatin Adriamycin Ifosfamide | 18 Years - | M.D. Anderson Cancer Center | |
| TPO-Mimetic Use in Children for Hematopoietic Failure | NCT04478227 | Bone Marrow Fai... Aplastic Anemia Thrombocytopeni... Refractory Cyto... Myelodysplastic... | Romiplostim | 0 Years - 21 Years | University of Iowa | |
| Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC) | NCT00413283 | Lung Cancer Chemotherapy-In... Non-Small Cell ... Cancer Lung Neoplasms Oncology Solid Tumors Thrombocytopeni... | Romiplostim Placebo Gemcitabine Carboplatin Cisplatin | 18 Years - | Amgen | |
| Using Romiplostim to Treat Low Platelet Counts During Chemotherapy in People With Lymphoma | NCT04673266 | Lymphoma Patien... Thrombocytopeni... | Romiplostim | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Romiplostim Treatment of Thrombocytopenia in Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) | NCT00614523 | MDS Myelodysplastic... Thrombocytopeni... | Placebo Romiplostim | 18 Years - 90 Years | Amgen | |
| A Study of Romiplostim to Prevent Low Platelet Counts in Children and Young Adults Receiving Chemotherapy for Solid Tumors | NCT04671901 | Solid Tumor Solid Tumor, Ch... Solid Carcinoma | Romiplostim | 1 Year - 21 Years | Memorial Sloan Kettering Cancer Center | |
| Using Romiplostim to Treat Low Platelet Counts Following Chemotherapy and Autologous Hematopoietic Cell Transplantation in People With Blood Cancer | NCT04478123 | Multiple Myelom... Hodgkin Lymphom... Non-Hodgkin Lym... HDT-AHCT | Romiplostim | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer | NCT03937154 | Chemotherapy-in... | Romiplostim Placebo | 18 Years - 100 Years | Amgen | |
| Determination of Safe Dose of Romiplostim (AMG 531) in Patients With Myelodysplastic Syndromes (MDS) | NCT00303472 | Thrombocytopeni... MDS Myelodysplastic... Refractory Cyto... | Romiplostim | 18 Years - | Amgen | |
| Prevention of Thrombocytopenia in Glioblastoma Patients | NCT02227576 | Thrombocytopeni... Glioblastoma | Romiplostim | 18 Years - | University Hospital, Lille | |
| AMG 531 in Patients With Advanced Malignancy Receiving Treatment With Carboplatin | NCT00147225 | Solid Tumors Advanced Cancer | AMG 531 Carboplatin Adriamycin Ifosfamide | 18 Years - | M.D. Anderson Cancer Center | |
| Phase II Trial of Romiplostim for Thrombocytopenia Induced by Lomustine at First Progression of MGMT Promoter-meth Glioblastoma | NCT04933942 | First Progressi... | Lomustine Romiplostim | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Secondary Prophylaxis in Non-Hodgkin Lymphoma (NHL) and Chemotherapy-induced Thrombocytopenia | NCT01516619 | Non-Hodgkin Lym... | Romiplostim | 18 Years - | IRCCS San Raffaele | |
| Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer | NCT03362177 | Chemotherapy-in... | Romiplostim Placebo | 18 Years - 100 Years | Amgen | |
| Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving Chemotherapy | NCT01676961 | Refractory Mult... Stage I Multipl... Stage II Multip... Stage III Multi... Thrombocytopeni... | romiplostim | 18 Years - | NYU Langone Health | |
| Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC) | NCT00413283 | Lung Cancer Chemotherapy-In... Non-Small Cell ... Cancer Lung Neoplasms Oncology Solid Tumors Thrombocytopeni... | Romiplostim Placebo Gemcitabine Carboplatin Cisplatin | 18 Years - | Amgen | |
| Determination of Safe Dose of Romiplostim (AMG 531) in Patients With Myelodysplastic Syndromes (MDS) | NCT00303472 | Thrombocytopeni... MDS Myelodysplastic... Refractory Cyto... | Romiplostim | 18 Years - | Amgen |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
